Results for 'Ken Schlosser'
Leadership Lab: 5 Ways Biopharma Execs Can Restore Trust, Retain Talent After Layoffs
Jun 25th • 4 mins read
Accelerated drug approvals in oncology: Pros and cons
Sep 14th • 4 mins read
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Aug 31st • 16 mins read
Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis
Jun 24th • 3 mins read
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
Jan 20th • 20 mins read
Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?
May 9th • 5 mins read
Medical affairs: The power behind redefining commercialization
Aug 2nd • 3 mins read
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years
Aug 26th • 2 mins read
Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program
Jun 5th • 6 mins read
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
May 28th • 5 mins read
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016
Aug 4th • 15 mins read